Your browser doesn't support javascript.
loading
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor, Oliver; Heinrich, Daniel; Mariados, Neil; Méndez Vidal, Maria José; Keizman, Daniel; Thellenberg Karlsson, Camilla; Peer, Avivit; Procopio, Giuseppe; Frank, Stephen J; Pulkkanen, Kalevi; Rosenbaum, Eli; Severi, Stefano; Trigo, José; Trandafir, Lucia; Wagner, Volker; Li, Rui; Nordquist, Luke T.
Afiliação
  • Sartor O; Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, Louisiana.
  • Heinrich D; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
  • Mariados N; Department of Radiation Oncology, Associated Medical Professionals of New York, PLLC, Syracuse, New York.
  • Méndez Vidal MJ; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain.
  • Keizman D; Genitourinary Oncology Unit, Meir Medical Center, Kfar-Saba, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Thellenberg Karlsson C; Department of Radiation Sciences, Cancer Center Norrlands University, Umeå, Sweden.
  • Peer A; Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
  • Procopio G; Division of Medical Oncology, Fondazione Istituto Nazionale Tumori Oncologia Medica Genitourinaria, Milan, Italy.
  • Frank SJ; Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Pulkkanen K; Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
  • Rosenbaum E; Uro-Oncology Unit, Rabin Medical Center, Davidoff Center, Petah Tikva, Israel.
  • Severi S; Nuclear Medicine Therapeutic Unit, Romagnolo Scientific Institute for the Study and Care of Cancer, IRST IRCCS, Meldola, Italy.
  • Trigo J; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Trandafir L; Global Clinical Development, Bayer Pharma AG, Basel, Switzerland.
  • Wagner V; Global Clinical Development, Bayer Pharma AG, Basel, Switzerland.
  • Li R; Global Research and Development Statistics, Bayer HealthCare Pharmaceuticals, Whippany, New Jersey.
  • Nordquist LT; Department of Medical Oncology, GU Research Network, LLC, Omaha, Nebraska.
Prostate ; 79(14): 1683-1691, 2019 10.
Article em En | MEDLINE | ID: mdl-31442327
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_other_malignant_neoplasms / 6_prostate_cancer Assunto principal: Neoplasias Ósseas / Rádio (Elemento) / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Prostate Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_other_malignant_neoplasms / 6_prostate_cancer Assunto principal: Neoplasias Ósseas / Rádio (Elemento) / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Prostate Ano de publicação: 2019 Tipo de documento: Article